Evotec SE
General information
Evotec SE
Essener Bogen 7
Manfred Eigen Campus
22419 Hamburg, Hamburg
Germany
Contact person: Werner Lanthaler, Chief Executive Officer
Company main phone: +49 (40) 560810
Company main fax: +49 (40) 56081222
Website: https://www.evotec.com
Essener Bogen 7
Manfred Eigen Campus
22419 Hamburg, Hamburg
Germany
Contact person: Werner Lanthaler, Chief Executive Officer
Company main phone: +49 (40) 560810
Company main fax: +49 (40) 56081222
Website: https://www.evotec.com
| Year founded: | 1993 |
| Source of foundation: | Independent foundation |
| No. of employees: |
Worldwide: 5067 |
Corporate description / mission:
Evotec is a drug discovery alliance and development partnership company focused on progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. The company has existing development partnerships and product candidates both in clinical and pre-clinical development. Evotec’s iPSC platform is closely connected to a variety of in-house key technologies, defining disease signatures and causal relationships between genetic mutations and perturbation of specific molecular pathways.
Evotec is a drug discovery alliance and development partnership company focused on progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. The company has existing development partnerships and product candidates both in clinical and pre-clinical development. Evotec’s iPSC platform is closely connected to a variety of in-house key technologies, defining disease signatures and causal relationships between genetic mutations and perturbation of specific molecular pathways.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Headquarters: Yes
IPO (year): 1999
Remarks on ownership / listings
The company has been operating and managing its business activities under the two segments EVT Execute and EVT Innovate.
The company has been operating and managing its business activities under the two segments EVT Execute and EVT Innovate.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
| Distribution: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 24 | |
| Phase I: | 11 | |
| Phase II: | 3 | |
| Phase III: | 2 |
Description of products:
EVT201
Eliapixant (BAY1817080)
EVT894, etc.
EVT201
Eliapixant (BAY1817080)
EVT894, etc.
Technology used:
iPSC platform
iPSC platform
Financing details
Fiscal year (end of) 2022
| Revenues: | EUR 751.45M | |
| R&D expenses: | EUR 76.64M |
| No. of shares: | 177'186'000 | |
| Market cap. / valuation: | EUR 3'430.31M |
Collaborations & Clients
Partnering strategy / collaborations:
Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.
Bayer
Boehringer Ingelheim
BMS
CHDI
Galapagos
Merck
Novartis
Novo Nordisk
Pfizer
Sanofi
Takeda
UCB etc.
Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.
Bayer
Boehringer Ingelheim
BMS
CHDI
Galapagos
Merck
Novartis
Novo Nordisk
Pfizer
Sanofi
Takeda
UCB etc.
© 2023 Biotechgate by Venture Valuation